School of Medicine, College of Medicine, I-Shou University, Kaohsiung, Taiwan; Division of Pulmonary Medicine, Department of Internal Medicine, E-Da Hospital, I-Shou University, Kaohsiung, Taiwan, College of Medicine, I-Shou University, Kaohsiung, Taiwan.
Institute of Biotechnology and Chemical Engineering, I-Shou University, Kaohsiung, Taiwan; Department of Pharmacy, E-Da Hospital, Kaohsiung, Taiwan.
J Infect Public Health. 2022 Aug;15(8):896-901. doi: 10.1016/j.jiph.2022.07.001. Epub 2022 Jul 7.
This meta-analysis of randomized controlled trials (RCTs) investigated the usefulness of mesenchymal stromal cells (MSCs) to treat patients with COVID-19.
PubMed, Embase, Ovid MEDLINE, the Cochrane Library, and Clinicaltrials.gov were searched for RCTs published before November 7, 2021. Only RCTs that compared the clinical efficacy and safety of MSCs with other alternative treatments or placebos in the treatment of patients with COVID-19 were included.
Six RCTs were included, in which the MSC and control groups consisted of 158 and 135 patients, respectively. The patients who received MSCs had a significantly lower 28-day mortality rate (7.6% vs 21.5%; OR, 0.18; 95% CI, 0.06-0.52; I = 0%) and significantly higher clinical improvement rate (OR, 6.05; 95% CI, 2.31-15.83; I = 0%) than the controls. The patients who received MSCs were associated with a similar risk of adverse events (AEs) and serious AEs to the control group (AEs: OR, 33; 95% CI, 0.09-1.18; I = 59%; serious AEs: OR, 0.30; 95% CI, 0.02-4.41; I = 53%).
MSC treatment may help to improve the clinical outcomes of patients with COVID-19. In addition, MSC treatment appears to be a safe therapeutic option for patients with COVID-19.
本荟萃分析的随机对照试验（RCTs）旨在研究间充质干细胞（MSCs）在治疗 COVID-19 患者中的有效性。
检索了 PubMed、Embase、Ovid MEDLINE、Cochrane 图书馆和 Clinicaltrials.gov 中截至 2021 年 11 月 7 日发表的 RCTs。仅纳入比较 MSCs 与 COVID-19 患者其他替代治疗或安慰剂治疗的临床疗效和安全性的 RCTs。
共纳入 6 项 RCTs，其中 MSC 组和对照组分别包含 158 例和 135 例患者。接受 MSCs 治疗的患者 28 天死亡率显著降低（7.6% vs 21.5%；OR，0.18；95%CI，0.06-0.52；I = 0%），临床改善率显著升高（OR，6.05；95%CI，2.31-15.83；I = 0%）。接受 MSCs 治疗的患者与对照组不良事件（AE）和严重 AE 的风险相似（AE：OR，33；95%CI，0.09-1.18；I = 59%；严重 AE：OR，0.30；95%CI，0.02-4.41；I = 53%）。
MSC 治疗可能有助于改善 COVID-19 患者的临床结局。此外，MSC 治疗似乎是 COVID-19 患者安全的治疗选择。
